Intercept Pharmaceuticals (ICPT) Downgraded to Strong Sell at BidaskClub

Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday.

Other equities analysts have also issued research reports about the company. Zacks Investment Research lowered Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Goldman Sachs Group reissued a “neutral” rating and set a $79.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, October 6th. Citigroup set a $74.00 price objective on Intercept Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, December 29th. Leerink Swann lowered their price objective on Intercept Pharmaceuticals from $120.00 to $66.00 and set a “market perform” rating for the company in a research report on Saturday, September 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. Intercept Pharmaceuticals has an average rating of “Hold” and an average target price of $140.24.

Shares of Intercept Pharmaceuticals (ICPT) opened at $52.72 on Tuesday. Intercept Pharmaceuticals has a 52 week low of $51.53 and a 52 week high of $135.59. The company has a market capitalization of $1,320.00, a price-to-earnings ratio of -3.56 and a beta of -2.05. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, topping analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million during the quarter, compared to analyst estimates of $36.95 million. During the same quarter last year, the firm posted ($3.59) earnings per share. The firm’s revenue was up 697.9% on a year-over-year basis. analysts expect that Intercept Pharmaceuticals will post -13.36 EPS for the current fiscal year.

Several large investors have recently modified their holdings of ICPT. WFG Advisors LP increased its holdings in shares of Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares in the last quarter. IFP Advisors Inc increased its holdings in shares of Intercept Pharmaceuticals by 90.9% during the third quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 1,182 shares in the last quarter. QCM Cayman Ltd. bought a new position in shares of Intercept Pharmaceuticals during the second quarter valued at $237,000. Birchview Capital LP bought a new position in shares of Intercept Pharmaceuticals during the third quarter valued at $250,000. Finally, Oppenheimer & Co. Inc. increased its holdings in shares of Intercept Pharmaceuticals by 145.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 2,833 shares in the last quarter. Hedge funds and other institutional investors own 73.76% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Intercept Pharmaceuticals (ICPT) Downgraded to Strong Sell at BidaskClub” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3143947/intercept-pharmaceuticals-icpt-downgraded-to-strong-sell-at-bidaskclub.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.